Adverum Biotechnologies, Inc.

NasdaqCM:ADVM Rapporto sulle azioni

Cap. di mercato: US$154.1m

Adverum Biotechnologies Gestione

Gestione criteri di controllo 4/4

Adverum Biotechnologies' CEO is Laurent Fischer, appointed in Jun 2020, has a tenure of 4.42 years. total yearly compensation is $1.55M, comprised of 43.4% salary and 56.6% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $521.76K. The average tenure of the management team and the board of directors is 2.8 years and 4.5 years respectively.

Informazioni chiave

Laurent Fischer

Amministratore delegato

US$1.5m

Compenso totale

Percentuale dello stipendio del CEO43.4%
Mandato del CEO4.4yrs
Proprietà del CEO0.3%
Durata media del management2.8yrs
Durata media del Consiglio di amministrazione4.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Feb 24
We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Sep 07
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Aug 11

Adverum gains 13% to reach three-month high after Truist upgrade

Jul 07

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

May 12
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Jul 17
We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Adverum Biotechnologies: An Uncertain Path Forward

May 05

Adverum Bio presents long-term data from ADVM-022 trial in wet AMD

May 03

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Apr 06
We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

Feb 13
Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy

Feb 02

Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares

Jan 22
Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares

Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market

Jan 11

Adverum Biotechnologies announces new GMP gene therapy manufacturing facility

Jan 07

How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?

Dec 31
How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Laurent Fischer rispetto agli utili di Adverum Biotechnologies?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$100m

Mar 31 2024n/an/a

-US$113m

Dec 31 2023US$2mUS$672k

-US$117m

Sep 30 2023n/an/a

-US$126m

Jun 30 2023n/an/a

-US$133m

Mar 31 2023n/an/a

-US$146m

Dec 31 2022US$3mUS$646k

-US$155m

Sep 30 2022n/an/a

-US$156m

Jun 30 2022n/an/a

-US$154m

Mar 31 2022n/an/a

-US$155m

Dec 31 2021US$9mUS$621k

-US$146m

Sep 30 2021n/an/a

-US$149m

Jun 30 2021n/an/a

-US$138m

Mar 31 2021n/an/a

-US$123m

Dec 31 2020US$22mUS$327k

-US$118m

Compensazione vs Mercato: Laurent's total compensation ($USD1.55M) is about average for companies of similar size in the US market ($USD1.48M).

Compensazione vs guadagni: Laurent's compensation has been consistent with company performance over the past year.


AMMINISTRATORE DELEGATO

Laurent Fischer (60 yo)

4.4yrs

Mandato

US$1,546,477

Compensazione

Dr. Laurent Fischer, M.D., serves as Chair of the Board of Teal Omics Inc. He has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He is Advisor of FORM Life Ventures. He...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Laurent Fischer
President4.4yrsUS$1.55m0.34%
$ 521.8k
Linda Rubinstein
CFO, Principal Financial Officer & Principal Accounting Officer1.9yrsUS$2.30m0.048%
$ 74.1k
Kishor Soparkar
Chief Operating Officer3.4yrsUS$903.02k0.13%
$ 205.9k
Setareh Seyedkazemi
Chief Development Officer2.8yrsUS$799.36k0.026%
$ 39.8k
Rabia Ozden
Chief Medical Officerless than a yearUS$94.20k0%
$ 0
R. Ramelmeier
Chief Technology Officer1.3yrsNessun datoNessun dato
Romuald Corbau
Chief Scientific Officerless than a yearNessun datoNessun dato
John Rakow
Senior VP & General Counsel3.3yrsUS$1.33m0.031%
$ 48.0k
Dena House
Chief People Officer5.3yrsNessun datoNessun dato
Carla Fiankan
Senior Vice President of Regulatory Affairs2.8yrsNessun datoNessun dato
Michael Steel
Senior Vice President of Quality3.1yrsNessun datoNessun dato
Heikki Jouttijarvi
Senior VP of Manufacturing & Supply Chain Management and Head of Technical Operationsno dataNessun datoNessun dato

2.8yrs

Durata media

56.5yo

Età media

Gestione esperta: ADVM's management team is considered experienced (2.8 years average tenure).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Laurent Fischer
President4.4yrsUS$1.55m0.34%
$ 521.8k
James Scopa
Independent Director5.5yrsUS$111.70k0.050%
$ 76.6k
Scott Whitcup
Independent Director4.6yrsUS$106.70k0%
$ 0
David Boyer
Scientific Advisory Board Memberno dataNessun datoNessun dato
C. Machado
Independent Chairman7.7yrsUS$163.80k0.042%
$ 65.3k
Jeffrey Heier
Scientific Advisory Board Memberno dataNessun datoNessun dato
Reed Tuckson
Independent Director3.8yrsUS$99.20k0%
$ 0
Dawn Svoronos
Independent Director3.9yrsUS$106.70k0.024%
$ 37.1k
Mark Lupher
Independent Director5.5yrsUS$99.20k0.063%
$ 96.3k
Charles Wykoff
Scientific Advisory Board Memberno dataNessun datoNessun dato
Arshad Khanani
Scientific Advisory Board Memberno dataNessun datoNessun dato
Szilard Kiss
Directorless than a yearNessun datoNessun dato

4.5yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: ADVM's board of directors are considered experienced (4.5 years average tenure).